Bullous pemphigoid outcome measurement: a scoping review of outcome heterogeneity and trends in clinical research of treatments
Over the past two decades, there has been considerable heterogeneity in reported outcomes and OMIs in BP research. Despite standardization efforts, most studies lack well-defined, consistent outcomes. Redefinition of some endpoints and a consensus-based approach towards outcome uniformity should bridge regulatory requirements with validated sensitive measurement and PROs. This approach would enhance the clinical relevance of trial endpoints while maintaining standardization, ultimately advancing research quality and therapeutic development.
Authors
- Sjoukje van der Werf (ORCID: https://orcid.org/0000-0001-5856-7657)
- Joost M. Meijer (ORCID: https://orcid.org/0000-0001-7654-3528)
- P. Joly (ORCID: https://orcid.org/0000-0002-5734-0255)
- Barbara Horváth (ORCID: https://orcid.org/0000-0001-8559-3674)
- Maria C. Bolling (ORCID: https://orcid.org/0000-0003-2086-9363)
- Phyllis I. Spuls (ORCID: https://orcid.org/0000-0002-6035-2863)
- Eva W H Korte (ORCID: https://orcid.org/0000-0001-9166-5654)
- Marjolein A J Hiel (ORCID: https://orcid.org/0000-0002-7715-1697)
- Billal Tedbirt (ORCID: https://orcid.org/0000-0001-7404-010X)
- Marc Yale (ORCID: https://orcid.org/0009-0006-6722-3569)
Institutions
- University Medical Center Groningen (NL)
- Inserm (FR)
- Amsterdam UMC Location University of Amsterdam (NL)
- Normandie Université (FR)
- Institute of Infection and Immunity (CA)
- Université de Rouen Normandie (FR)
- University of Amsterdam (NL)
Publication Details
- Journal
- British Journal of Dermatology
- Published
- 2025-11-22
- DOI
- https://doi.org/10.1093/bjd/ljaf471
- Primary Topic
- Autoimmune Bullous Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Celgene
- Novartis Pharma
- UCB Pharma
- Cilag